News

Dozens of cases verify the efficacy of unique compounds Thanks to the pioneering work of Luminec Executive Advisor Dr. Susana Alcázar-Leyva, Luminec’s X-2™ and CRO-50™ … Read More

Promising COVID-19 countermeasure submitted; meeting requested Luminec Pharmaceuticals has completed its initial submission and request for meeting to the National Institute of Allergies and Infectious … Read More

Formulations proved in previous worldwide Coronavirus outbreaks are a promising solution for the current pandemic. Luminec Pharmaceuticals, Inc. announced that it will submit a market … Read More

In this interview, the co-founder of Luminec Pharmaceuticals discusses his development of The Schutt Paradigm and the company’s seminal products,  Triamino™ and TAFA400™.

Luminec Pharmaceuticals has added an ingredient to its products that enhances the delivery of their active ingredients. SK 713™, developed by Luminec CEO Steven Kushner, … Read More

Luminec Pharmaceuticals is proud to announce an exclusive supplier relationship with one of the world’s most prominent practitioners in the hair restoration field. Dr. Ahmed … Read More

TAFA400™ Foam, see new product from Luminec Pharmaceuticals, has been proved effective in treating Cradle Cap (Infantile Seborrheic Dermatitis).

Luminec Pharmaceuticals is now actively producing over 20 products based on our proprietary formulations Triamino™ and TAFA400™, enhanced by PH-713™. The company has plans for … Read More

  Luminec Pharmaceuticals is launching a slew of new products to meet the needs of consumers and healthcare professionals to address needs in a variety … Read More